Curability of patients with lymph node metastases from extremity soft-tissue sarcoma.
Autor: | Basile G; Musculoskeletal Oncology Unit, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.; Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada., Mattei JC; Musculoskeletal Oncology Unit, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.; Division of Orthopaedic Surgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada., Alshaygy I; Musculoskeletal Oncology Unit, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.; Division of Orthopaedic Surgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada., Griffin AM; Musculoskeletal Oncology Unit, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.; Division of Orthopaedic Surgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada., Catton CN; Radiation Medicine Program, Princess Margaret Cancer Center, Toronto, Ontario, Canada.; Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada., Chung PW; Radiation Medicine Program, Princess Margaret Cancer Center, Toronto, Ontario, Canada.; Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada., Shultz DB; Radiation Medicine Program, Princess Margaret Cancer Center, Toronto, Ontario, Canada.; Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada., Razak ARA; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Demicco EG; Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada., Ferguson PC; Musculoskeletal Oncology Unit, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.; Division of Orthopaedic Surgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada., Wunder JS; Musculoskeletal Oncology Unit, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.; Division of Orthopaedic Surgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada. |
---|---|
Jazyk: | angličtina |
Zdroj: | Cancer [Cancer] 2020 Dec 01; Vol. 126 (23), pp. 5098-5108. Date of Electronic Publication: 2020 Sep 10. |
DOI: | 10.1002/cncr.33189 |
Abstrakt: | Background: Lymph node metastases (LNM) rarely occur in adult extremity soft-tissue sarcoma (STS), affecting approximately 5% of patients. To the authors' knowledge, few studies to date have evaluated the prognosis and survival of patients with LNM. Methods: A retrospective review was performed of a single-center, prospectively collected STS database. Demographic, treatment, and oncologic data for patients with STS of the extremity with LNM were obtained from clinical and radiographic records. Results: Of 2689 patients with extremity STS, a total of 120 patients (4.5%) were diagnosed with LNM. LNM occurred most frequently among patients diagnosed with clear cell sarcoma (27.6%), epithelioid sarcoma (21.9%), rhabdomyosarcoma (17.3%), angiosarcoma (14.0%), and extraskeletal myxoid chondrosarcoma (9.3%). A total of 98 patients (81.7%) underwent LNM surgical resection. Patients with isolated LNM had a greater 5-year overall survival (57.3%) compared with patients with American Joint Committee on Cancer (AJCC) eighth edition stage IV STS with only systemic metastases (14.6%) or both LNM and systemic disease (0%; P < .0001). Patients with isolated LNM had an overall survival rate (52.9%) similar to that of patients with localized AJCC stage III tumors (ie, large, high-grade tumors) (49.3%) (P = .8). Patients with late, isolated, metachronous LNM had a 5-year overall survival rate (61.2%) that was similar to that of patients with isolated synchronous LNM at the time of presentation (53.6%) (P = .4). Conclusions: Many different types of STS develop LNM. Patients with extremity STS with isolated LNM should not be considered as having stage IV disease as they are according to the current AJCC eighth edition classification because they have significantly better survival than those with systemic metastases. Patients with isolated, late, metachronous LNM have a survival similar to that of patients with isolated synchronous LNM at the time of presentation. Lay Summary: The results of the current study demonstrated that patients diagnosed with isolated lymph node metastases have a prognosis similar to that of patients diagnosed with localized American Joint Committee on Cancer stage III soft-tissue sarcomas, which also equates to a significantly better overall survival compared with patients with systemic metastases. Therefore, the authors recommend modifications to the most recent eighth edition of the American Joint Committee on Cancer staging system to clearly distinguish patients with isolated lymph node metastases to acknowledge their better prognosis compared with those with systemic metastases. (© 2020 American Cancer Society.) |
Databáze: | MEDLINE |
Externí odkaz: |